<DOC>
	<DOC>NCT01334190</DOC>
	<brief_summary>This will be a non-comparative prospective observational study of women using Zarin as a primary method of contraception in Kenya. It will be conducted in close collaboration with the Kenya MoH in several MoH-affiliated clinics that have experience with implants and sufficient expected flow of implant users per month. The investigators will enroll a total of 600 women divided into two cohorts in this one-year prospective study: - a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment; and - a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrollment only if they have complications, medical problems, pregnancy, or want to remove the implant The main study outcomes are pregnancy, immediate and delayed complications associated with insertion or removal, adverse events, early discontinuation and reasons for discontinuation, and level of women's satisfaction with Zarin services.</brief_summary>
	<brief_title>A Prospective Observational Study of the Performance of Zarin in Kenya</brief_title>
	<detailed_description>A non-comparative prospective observational study of women using Zarin as a primary method of contraception in Kenya. It will be conducted in close collaboration with the Kenya MoH in several MoH-affiliated clinics that have experience with implants and sufficient expected flow of implant users per month. The investigators will enroll a total of 600 women divided into two cohorts in this one-year prospective study: - a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment; and - a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrollment only if they have complications, medical problems, pregnancy, or want to remove the implant The main study outcomes are pregnancy, immediate and delayed complications associated with insertion or removal, adverse events, early discontinuation and reasons for discontinuation, and level of women's satisfaction with Zarin services.</detailed_description>
	<criteria>be aged 1844 years, inclusive be willing to sign an informed consent document be willing to give contact information for follow up agree to return for followup visits have decided to receive Zarin as a method of contraception and met the clinic criteria for eligibility of this method of contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquired immunodeficiency syndrome</keyword>
	<keyword>ALT (SGPT) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST (SGOT) aspartate aminotransferase</keyword>
	<keyword>DCF data collection forms</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA (U.S.) Food and Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guidelines</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference of Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international units</keyword>
	<keyword>mg milligram(s)</keyword>
	<keyword>mm3 cubic millimeter(s)</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>Âµg microgram</keyword>
	<keyword>ULN upper limit of the normal range</keyword>
	<keyword>WB Western Blot</keyword>
	<keyword>post-marketing monitoring</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>acceptability</keyword>
</DOC>